Bristol-Myers Squibb Co. (BMY) Stock Could Soon Reward Patient Investors

Bristol-Myers Squibb Co. (NYSE: BMY) is -2.92% lower on its value in year-to-date trading and has touched a low of $47.58 and a high of $73.84 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BMY stock was last observed hovering at around $48.71 in the last trading session, with the day’s gains setting it 1.1%.

Currently trading at $49.81, the stock is 0.62% and -1.16% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 15.41 million and changing 2.26% at the moment leaves the stock -14.31% off its SMA200. BMY registered -32.37% loss for a year compared to 6-month loss of -18.73%. The firm has a 50-day simple moving average (SMA 50) of $2.95 and a 200-day simple moving average (SMA200) of $7.13.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -1.68% gain in the last 1 month and extending the period to 3 months gives it a -4.98%, and is 2.26% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.76% over the week and 2.07% over the month.

Bristol-Myers Squibb Co. (BMY) has around Jan 04 2024 employees, a market worth around $101.35B and $45.01B in sales. Current P/E ratio is 12.90 and Fwd P/E is 6.99. Profit margin for the company is 17.83%. Distance from 52-week low is 4.69% and -32.54% from its 52-week high. The company has generated returns on investments over the last 12 months (12.81%).

Bristol-Myers Squibb Co. quarterly earnings per share for the current quarter are estimated at $1.6 with sales reaching $11.45B over the same period.The EPS is expected to shrink by -8.64% this year, but quarterly earnings will post 2.30% year-over-year. Quarterly sales are estimated to grow 1.00% in year-over-year returns.

Bristol-Myers Squibb Co. (BMY) Top Institutional Holders

3,007 institutions hold shares in Bristol-Myers Squibb Co. (BMY), with institutional investors hold 79.67% of the company’s shares. The shares outstanding are 2.10B, and float is at 2.03B with Short Float at 1.53%. Institutions hold 79.59% of the Float.

The top institutional shareholder in the company is Vanguard Group Inc with over 203.74 million shares valued at $13.03 billion. The investor’s holdings represent 9.75% of the BMY Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 172.67 million shares valued at $11.04 billion to account for 8.27% of the shares outstanding. The other top investors are JP Morgan Chase & Company which holds 103.31 million shares representing 4.95% and valued at over $6.61 billion, while State Street Corporation holds 4.43% of the shares totaling 92.57 million with a market value of $5.92 billion.

Bristol-Myers Squibb Co. (BMY) Insider Activity

A total of 2 insider transactions have happened at Bristol-Myers Squibb Co. (BMY) in the last six months, with sales accounting for 2 and purchases happening 0 times. The most recent transaction is an insider purchase by BOERNER CHRISTOPHER S. ,the company’sChief Executive Officer. SEC filings show that BOERNER CHRISTOPHER S. bought 2,000 shares of the company’s common stock on Dec 05 at a price of $49.78 per share for a total of $99560.0. Following the purchase, the insider now owns 82672.0 shares.

Bristol-Myers Squibb Co. disclosed in a document filed with the SEC on Nov 28 that BOERNER CHRISTOPHER S. (Chief Executive Officer) bought a total of 3,071 shares of the company’s common stock. The trade occurred on Nov 28 and was made at $48.86 per share for $0.15 million. Following the transaction, the insider now directly holds 79384.0 shares of the BMY stock.

Still, SEC filings show that on Nov 20, Samuels Theodore R. II (Director) acquired 8,500 shares at an average price of $49.81 for $0.42 million. The insider now directly holds 35,500 shares of Bristol-Myers Squibb Co. (BMY).

Bristol-Myers Squibb Co. (BMY): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -3.68% down over the past 12 months. Pfizer Inc. (PFE) that is -37.35% lower over the same period.